AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 28376732
Drug: Daily consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily consumption of vegetables with dinner
Trial: 23647285
Drug: Antidepressant Medications
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antidepressant Medications (ADMs)
Trial: 23350342
Drug: Parathyroid hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Parathyroid hormone (PTH) 1-84
Trial: 19482956
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral care with 0.12% chlorhexidine digluconate
Trial: 19482956
Drug: Standard oral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard oral care plus electric toothbrushing
Trial: 12441260
Drug: VAC (vincristine,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VAC (vincristine, doxorubicin, cyclophosphamide) and VIAc (vincristine, ifosfamide, actinomycin) chemotherapy regimen
Trial: 12441260
Drug: Surgery, surgery+radiotherapy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery, surgery+radiotherapy, or radiotherapy only as local treatment
Trial: 12441260
Drug: Previous studies
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous studies with three-drug VAC regimen (REA-1) and four-drug VACAc regimen (REA-2 and REN-1)
Trial: 12441260
Drug: Previous study
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Previous study (REN-2) with a six-drug regimen
Trial: 10515844
Drug: GM‐CSF plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GM‐CSF plus sodium stibogluconate (20 mg/kg‐1/day‐1 for 20 days)
Trial: 10515844
Drug: Placebo (saline)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (saline) plus sodium stibogluconate (20 mg/kg‐1/day‐1 for 20 days)
Trial: 7722140
Drug: NG-mononmethyl-L-arginine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG-mononmethyl-L-arginine (16 mumol/min) in untreated patients
Trial: 7722140
Drug: NG-mononmethyl-L-arginine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG-mononmethyl-L-arginine (16 mumol/min) in control subjects
Trial: 7722140
Drug: NG-mononmethyl-L-arginine (16
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NG-mononmethyl-L-arginine (16 mumol/min) in treated patients
Trial: 1723464
Drug: Nitrendipine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrendipine (2 x 10 mg daily)
Trial: 7347558
Drug: Amantadine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amantadine 300 mg/day
Trial: 7347558
Drug: Rimantadine 300
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rimantadine 300 mg/day
Trial: 6746357
Drug: Radiotherapy (first
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiotherapy (first 10 Gy in five consecutive daily fractions)
Trial: 24584549
Drug: Sitagliptin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sitagliptin (single oral dose)
Trial: 21770837
Drug: Minimal stimulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Minimal stimulation protocol (5 days CC 100 mg/day then 150 IU uFSH on cycle day 9)
Trial: 21970545
Drug: Clomiphene citrate
RxNorm normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Clomiphene citrate (CC) only
Trial: 19952860
Drug: Hib-MenC-TT vaccine
RxNorm normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hib-MenC-TT vaccine coadministered with MMR vaccine
Trial: 17224218
Drug: MMR vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR vaccine alone
Trial: 15763054
Drug: Somatostatin administered
RxNorm normalized name: somatostatin
DrugBank: Somatostatin (DB09099)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Somatostatin administered intravenously at a dosage of 250 mug/h for consecutive 72 hours
Trial: 15763054
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group treated with non-surgical integrated traditional Chinese and Western medicine
Trial: 12428174
Drug: Pyridoxine supplementation
RxNorm normalized name: PYRIDOXINE
DrugBank: Pyridoxine phosphate (DB02209)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pyridoxine supplementation (25 mg/day) for 45 days
Trial: 7781401
Drug: Combination chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination chemotherapy with etoposide/cisplatin
Trial: 7781401
Drug: Chemotherapy/chest irradiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chemotherapy/chest irradiation
Trial: 7781401
Drug: Surgery as
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgery as sole treatment
Trial: 2340741
Drug: 1.0 U
RxNorm normalized name: Nutren 1.0 Ultrapak
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.0 U heparin/mL
Trial: 2340741
Drug: 0.25 U
RxNorm normalized name: collagenase 0.25 UNT/MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25 U heparin/mL
Trial: 30843921
Drug: MMR-Bio vaccine
RxNorm normalized name: varicella-zoster virus vaccine live (Oka-Merck) strain
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MMR-Bio vaccine
Trial: 24437236
Drug: Cefixime (suprax
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cefixime (suprax solutab) 400 mg 1 time a day for 7 days
Trial: 24437236
Drug: Amoxicillin/clavulanate (amoksiklav)
DrugBank: Amoxicillin (DB01060)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Amoxicillin/clavulanate (amoksiklav) 625 mg 3 times a day for 7 days
Trial: 17513537
Drug: Topical morphine
RxNorm normalized name: morphine Topical Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical morphine sulphate
Trial: 17513537
Drug: Intrasite gel
RxNorm normalized name: Intrasite Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrasite gel and water (placebo)
Trial: 15309452
Drug: NUTRIOSE FB
RxNorm normalized name: FB-825
DrugBank: FB-825 (DB17598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NUTRIOSE FB (low-digestible carbohydrate) at a level of 100 g DM/d
Trial: 12058086
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of W-P MCV and W-P SCV
Trial: 10418043
Drug: Acyclovir (ACV)
RxNorm normalized name: Acyclovir
DrugBank: Acyclovir (DB00787)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Acyclovir (ACV) secondary prophylaxis, mean posology 2,400 mg (1,600‐4,000) per day, during mean 10 months (median 4 months)
Trial: 7574048
Drug: PCHE equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCHE equivalent to activity present in 2.5, 5, 7.5, 15, or 25 ml/kg of human plasma
Trial: 7574048
Drug: PCHE equivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PCHE equivalent to activity present in 25 ml/kg of human plasma
Trial: 27779456
Drug: Lercanidipine 10
RxNorm normalized name: lercanidipine 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lercanidipine 10 mg/day
Trial: 27779456
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (other antihypertensive treatments)
Trial: 22251379
Drug: Inductive reasoning
RxNorm normalized name: reductic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inductive reasoning training supplemented by weekly crossword and Sudoku puzzles
Trial: 12856494
Drug: Sham treatment;
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham treatment; duration not specified.
Trial: 10862808
Drug: Disulfiram (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (250 mg q.d., n = 11)
Trial: 10862808
Drug: Disulfiram (250
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Disulfiram (250 mg q.d.)
Trial: 9195495
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus DBD (200 mg/m2 orally on Days 1-10 every five weeks)
Trial: 9195495
Drug: RT plus
RxNorm normalized name: Recort Plus
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RT plus BCNU (200 mg/m2 intravenously every seven weeks)
Trial: 26073422
Drug: Surgical periodontal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Surgical periodontal treatment
Trial: 19422355
Drug: Ketamine (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ketamine (0.5 mg/kg i.v. bolus)
Trial: 16399963
Drug: Adherent to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adherent to medication
Trial: 16399963
Drug: Nonadherent to
RxNorm normalized name: Wong To Yick
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nonadherent to medication
Trial: 10654983
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone dipropionate (BDP) 168 microg twice daily (n = 51)
Trial: 10654983
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone dipropionate (BDP)
Trial: 8342393
Drug: Growth hormone
RxNorm normalized name: Growth hormone
DrugBank: Somatotropin (DB00052)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Growth hormone (GH) treatment, 0.018 IU/kg/day for 1 month followed by 0.036 IU/kg/day for 1 month
Trial: 2872717
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of synthetic somatostatin
Trial: 2872717
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of secretin (280 pmol/kg‐h)
Trial: 2872717
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of cholecystokinin (pharmacological dose)
Trial: 2872717
Drug: Intravenous infusion
RxNorm normalized name: intravenous infusion pump accessory
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusion of gastric inhibitory polypeptide (GIP) (physiological range)
Trial: 31197249
Drug: Antibiotic group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antibiotic group (omeprazole, amoxicillin, and clarithromycin; n=201)
Trial: 30124726
Drug: 30 mg
RxNorm normalized name: agar 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg Toreforant
Trial: 30124726
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg Toreforant
Trial: 26795846
Drug: Usual care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual care (placebo or medical treatment only)
Trial: 16194413
Drug: Benazepril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (10-20 mg/d) in group A (Scr 133-265 micromol/L)
Trial: 16194413
Drug: Benazepril (10-20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Benazepril (10-20 mg/d) in group B1 (Scr 266-442 micromol/L)
Trial: 16194413
Drug: Calcium-channel antagonist
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium-channel antagonist and/or beta-blocker and/or vasodilator in group B2 (control group)
Trial: 12598257
Drug: Large-dose gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Large-dose gentamicin (4 mg/kg)
Trial: 12598257
Drug: Modest-dose gentamicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modest-dose gentamicin (1.2 mg/kg)
Trial: 8470311
Drug: Chloroquine and
RxNorm normalized name: chloroquine and proguanil
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chloroquine and Proguanil combination (CQ+PROG)
Trial: 2983910
Drug: Etomidate (0.26
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etomidate (0.26 mg/kg i.v.)
Trial: 2983910
Drug: Thiopentone (5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Thiopentone (5.0 mg/kg i.v.)
Trial: 30245755
Drug: Kudiezi injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kudiezi injection
Trial: 30245755
Drug: Routine treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine treatments
Trial: 20145666
Drug: Peptide milk
RxNorm normalized name: MILK
DrugBank: Cow milk (DB10543)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Peptide milk (5 mg/day for 12 weeks, then 50 mg/day for 12 weeks)
Trial: 18176610
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-cysteine (NAC) 100 mg/kg per day as a 6-h i.v. infusion until normalization of bilirubin, ALT and AST values.
Trial: 9631802
Drug: N-acetyl-L-cysteine (NAC)
DrugBank: Acetylcysteine (DB06151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N-acetyl-L-cysteine (NAC)
Trial: 12526248
Drug: 7 days
RxNorm normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 days treatment
Trial: 7766742
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days treatment
Trial: 12526248
Drug: 21 days
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 21 days treatment
Trial: 12526248
Drug: 28 days
RxNorm normalized name: norethindrone
DrugBank: Norethisterone (DB00717)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 28 days treatment
Trial: 12526248
Drug: 14 days
RxNorm normalized name: ponesimod
DrugBank: Ponesimod (DB12016)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 14 days treatment (recommended duration)
Trial: 10486663
Drug: Physician's decision
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physician's decision not to modify treatment
Trial: 8595173
Drug: Adjuvant chemotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adjuvant chemotherapy with epidoxorubicin (EPI) 75 mg m‐2 on day 1, leucovorin (LV) 200 mg m‐2 on days 1‐3, and 5-fluorouracil (5‐FU) 450 mg m‐2 on days 1‐3, every 21 days for 7 months
Trial: 1910852
Drug: Digoxin treatment
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Digoxin treatment for 8 weeks (group 2)
Trial: 1910852
Drug: Discontinued digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinued digoxin treatment 5 weeks post-operation (group 3)
Trial: 1910852
Drug: Discontinued digoxin
RxNorm normalized name: Digoxin
DrugBank: Digoxin (DB00390)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Discontinued digoxin treatment 3 weeks post-operation (group 4)
Trial: 6383135
Drug: Lidocaine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (2 to 3 mg/kg total)
Trial: 6383135
Drug: Bretylium Tosylate
RxNorm normalized name: Bretylium Tosylate
DrugBank: Bretylium (DB01158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bretylium Tosylate (10 to 30 mg/kg total)
Trial: 6383135
Drug: Lidocaine (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lidocaine (2 to 3 mg/kg total) in patients on digitalis preparations
Trial: 6383135
Drug: Bretylium Tosylate
RxNorm normalized name: Bretylium Tosylate
DrugBank: Bretylium (DB01158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bretylium Tosylate (10 to 30 mg/kg total) in patients on digitalis preparations
Trial: 25287853
Drug: Pharmacist-based, patient-centered
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist-based, patient-centered medication review prior to discharge from hospital
Trial: 22797934
Drug: Standard dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard dose clopidogrel
Trial: 17430214
Drug: Bone marrow
RxNorm normalized name: bone marrow
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bone marrow stem cell therapy
Trial: 9492968
Drug: Double paper
RxNorm normalized name: paper birch pollen extract
DrugBank: Betula papyrifera pollen (DB10831)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Double paper source entry (forms entered twice using paper forms)
Trial: 2392791
Drug: System 22
RxNorm normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: System 22 Mizer with 50 mg pentamidine (3 ml fill)
Trial: 2392791
Drug: System 22
RxNorm normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: System 22 Mizer with 50 mg pentamidine (6 ml fill)
Trial: 2392791
Drug: Respirgard II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respirgard II with 50 mg pentamidine (3 ml fill)
Trial: 2392791
Drug: Respirgard II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respirgard II with 50 mg pentamidine (6 ml fill)
Trial: 2392791
Drug: System 22
RxNorm normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: System 22 Mizer with 150 mg pentamidine
Trial: 2392791
Drug: Respirgard II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respirgard II with 150 mg pentamidine
Trial: 2392791
Drug: System 22
RxNorm normalized name: methylphenidate
DrugBank: Methylphenidate (DB00422)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: System 22 Mizer with increased volume of fill (from 3 to 6 ml)
Trial: 2392791
Drug: Respirgard II
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Respirgard II with increased volume of fill (from 3 to 6 ml)
Trial: 27078991
Drug: Floating needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Floating needle therapy
Trial: 26076014
Drug: IN0 (before
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IN0 (before the start of the session at the inlet blood line filled with rinsing solution)
Trial: 26076014
Drug: Anti-Xa levels
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Xa levels below 0.3 IU/mL at the end of the session
Trial: 26076014
Drug: Anti-Xa above
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anti-Xa above 0.3 IU/mL at the end of the session
Trial: 23482444
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (meetings with a physical therapist twice a week for 10-13 weeks)
Trial: 19439067
Drug: GLP-1 infusion
RxNorm normalized name: Arg34Lys26-(N-ε-(γ-Glu(N-α-hexadecanoyl)))-GLP-1[7-37]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GLP-1 infusion (1.2 pmol/kg/min)
Trial: 21441444
Drug: Blocking endogenous
RxNorm normalized name: Ivy Block
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Blocking endogenous GLP-1 receptor action
Trial: 19656148
Drug: PGE(2) gel
RxNorm normalized name: PGE-1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: PGE(2) gel (2 mg)
Trial: 20614859
Drug: Ondansetron (Ond)
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ondansetron (Ond) 24 mg QD
Trial: 20614859
Drug: Fluoxetine (Fl)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (Fl) 5 mg QD + Ondansetron (Ond) 12 mg QD
Trial: 20614859
Drug: Fluoxetine (Fl)
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Fluoxetine (Fl) 10 mg QD + Ondansetron (Ond) 24 mg QD
Trial: 11347856
Drug: lacidipine (4‐6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: lacidipine (4‐6 mg o.d.)
Trial: 11347856
Drug: hydrochlorothiazide (HCTZ)
RxNorm normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: hydrochlorothiazide (HCTZ) (25‐50 mg o.d.)
Trial: 1377074
Drug: High-dose aprotinin
RxNorm normalized name: Aprotinin
DrugBank: Aprotinin (DB06692)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: High-dose aprotinin therapy (2 x 10(6) kallikrein inhibitor units intravenous bolus after induction of anaesthesia followed by continuous infusion of 0.5 x 10(6) kallikrein inhibitor units/h until the end of the operation)
Trial: 1377074
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no aprotinin therapy)
Trial: 6706301
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 mg per day of i.v. SAMe
Trial: 6706301
Drug: 800 mg
RxNorm normalized name: bran 800 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 800 mg per day of i.v. SAMe
Trial: 6706301
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no SAMe treatment)
Trial: 31113362
Drug: Stratified therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Stratified therapy based on mechanistic drivers and biomarkers of AF
Trial: 24438500
Drug: Low-dose computed
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose computed tomography (2 mSv)
Trial: 24438500
Drug: Standard-dose computed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-dose computed tomography (8 mSv)
Trial: 17303766
Drug: Motivational interviewing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Motivational interviewing (4 individual, weekly sessions)
Trial: 15675575
Drug: EGF receptor
RxNorm normalized name: Vegf receptor 2 kinase inhibitor i
DrugBank: VEGFR 2 Kinase inhibitor I (DB17061)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EGF receptor tyrosine kinase inhibitors (gefitinib and erlotinib)
Trial: 10422996
Drug: Pharmacist recommendations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pharmacist recommendations related to drug ordering
Trial: 1950033
Drug: Lovastatin 40
RxNorm normalized name: lovastatin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lovastatin 40 mg